Scheduled to begin operations in late 2026, the new facility will be the fifth plant the company opens in South Korea. According to SK Pharmteco, it will span 135,800 square feet and feature eight production trains with an output of tens of metric tons annually. The investment also includes peptide R&D facilities, CGMP kilo labs, and CGMP pilot plant for peptide manufacturing. With these resources, SK Pharmteco said that it can support early-stage clinical and commercial production with great flexibility. SK Pharmteco plans to hire over 300 new employees at the Sejong site.

Another part of the investment is the construction of the shell for a sixth manufacturing plant, which will allow a quick expansion of capacity in the future.

Joerg Ahlgrimm, CEO of SK Pharmteco, said: “By investing in this new facility, we’re increasing our capacity in Asia in line with our global expansion strategy and solidifying our position as a trusted partner for companies developing groundbreaking treatments, demonstrating our adaptability and reliability in a rapidly changing industry.”

“Our new facility represents a significant investment in our future and a commitment to delivering exceptional value to our customers,” said Yongwoo Park, SK Pharmteco’s president, Small Molecule, Asia. “By expanding our capacity and capabilities, we can offer even faster turnaround times, increased flexibility, and a higher level of quality.”